{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:03:10Z","timestamp":1790996590619,"version":"4.1.0"},"reference-count":178,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T00:00:00Z","timestamp":1553040000000},"content-version":"vor","delay-in-days":47,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010665","name":"Marie Sklodowska-Curie","doi-asserted-by":"publisher","award":["734718"],"award-info":[{"award-number":["734718"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.parkreldis.2019.02.042","type":"journal-article","created":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T13:26:10Z","timestamp":1551360370000},"page":"65-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Current treatment of behavioral and cognitive symptoms of Parkinson's disease"],"prefix":"10.1016","volume":"59","author":[{"given":"Irena","family":"Rektorova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.parkreldis.2019.02.042_bib1","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1007\/s00415-008-0994-4","article-title":"A comprehensive model of health-related quality of life in Parkinson's disease","volume":"255","author":"Visser","year":"2008","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.parkreldis.2019.02.042_bib2","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/ene.12950","article-title":"The impact of non-motor symptoms on the quality of life of Parkinson's disease patients: a longitudinal study","volume":"23","author":"Prakash","year":"2016","journal-title":"Eur. J. Neurol."},{"issue":"6","key":"10.1016\/j.parkreldis.2019.02.042_bib3","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.parkreldis.2015.03.024","article-title":"Neuropsychiatric symptoms and caregiver's burden in Parkinson's disease","volume":"21","author":"Martinez-Martin","year":"2015","journal-title":"Park. Relat. Disord."},{"issue":"Suppl 1","key":"10.1016\/j.parkreldis.2019.02.042_bib4","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1016\/S1353-8020(13)70040-3","article-title":"How to organize multispecialty care for patients with Parkinson's disease","volume":"20","author":"van der Marck","year":"2014","journal-title":"Park. Relat. Disord."},{"issue":"2","key":"10.1016\/j.parkreldis.2019.02.042_bib5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/mds.26016","article-title":"Clinical spectrum of impulse control disorders in Parkinson's disease","volume":"30","author":"Weintraub","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2019.02.042_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fpsyt.2011.00001","article-title":"Impulse control disorders: updated review of clinical characteristics and pharmacological management","volume":"2","author":"Schreiber","year":"2011","journal-title":"Front. Psychiatry"},{"issue":"3","key":"10.1016\/j.parkreldis.2019.02.042_bib7","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/mds.23501","article-title":"Impulsivity and compulsivity in drug-na\u00efve patients with Parkinson's disease","volume":"26","author":"Antonini","year":"2011","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.parkreldis.2019.02.042_bib8","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/mds.26099","article-title":"Management of impulse control disorders in Parkinson's disease: controversies and future approaches","volume":"30","author":"Samuel","year":"2015","journal-title":"Mov. Disord."},{"issue":"Suppl 1","key":"10.1016\/j.parkreldis.2019.02.042_bib9","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.parkreldis.2017.07.030","article-title":"The rise and fall of impulse control behavior disorders","volume":"46","author":"Cossu","year":"2018","journal-title":"Park. Relat. Disord."},{"issue":"6","key":"10.1016\/j.parkreldis.2019.02.042_bib10","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/ana.22356","article-title":"Impulse control disorders in Parkinson disease: a multicenter case - control study","volume":"69","author":"Voon","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.parkreldis.2019.02.042_bib11","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3389\/fneur.2018.00330","article-title":"Impulse-control disorders in Parkinson's disease: a meta-analysis and review of case-control studies","volume":"9","author":"Molde","year":"2018","journal-title":"Front. Neurol."},{"issue":"5","key":"10.1016\/j.parkreldis.2019.02.042_bib12","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archneurol.2010.65","article-title":"Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients","volume":"67","author":"Weintraub","year":"2010","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/j.parkreldis.2019.02.042_bib13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4103\/0972-2327.144311","article-title":"Impulse control disorders and related behaviours (ICD-RBs) in Parkinson's disease patients: assessment using \"Questionnaire for impulsive-compulsive disorders in Parkinson's disease\" (QUIP)","volume":"18","author":"Sharma","year":"2015","journal-title":"Ann. Indian Acad. Neurol."},{"issue":"2","key":"10.1016\/j.parkreldis.2019.02.042_bib14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.parkreldis.2011.09.007","article-title":"Impulse control disorders and depression in Finnish patients with Parkinson's disease","volume":"18","author":"Joutsa","year":"2012","journal-title":"Park. Relat. Disord."},{"issue":"3","key":"10.1016\/j.parkreldis.2019.02.042_bib15","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S1474-4422(17)30004-2","article-title":"Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update","volume":"16","author":"Voon","year":"2017","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.parkreldis.2019.02.042_bib16","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1136\/jnnp-2016-315277","article-title":"ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson's disease","volume":"88","author":"Antonini","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.parkreldis.2019.02.042_bib17","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/gps.2704","article-title":"Carer burden in apathy and impulse control disorders in Parkinson's disease","volume":"27","author":"Leroi","year":"2012","journal-title":"Int. J. Geriatr. Psychiatry"},{"issue":"1","key":"10.1016\/j.parkreldis.2019.02.042_bib18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jocn.2013.02.032","article-title":"Effect of impulse control disorders on disability and quality of life in Parkinson's disease patients","volume":"21","author":"Phu","year":"2014","journal-title":"J. Clin. Neurosci."},{"issue":"8","key":"10.1016\/j.parkreldis.2019.02.042_bib19","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s00702-018-1870-8","article-title":"Impulse control disorders in Parkinson's disease","volume":"125","author":"Marques","year":"2018","journal-title":"J. Neural. Transm."},{"issue":"5","key":"10.1016\/j.parkreldis.2019.02.042_bib20","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/mds.26154","article-title":"Patterns of cortical thickness associated with impulse control disorders in Parkinson's disease","volume":"30","author":"Biundo","year":"2015","journal-title":"Mov. Disord."},{"issue":"11","key":"10.1016\/j.parkreldis.2019.02.042_bib21","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/mds.23147","article-title":"Decreased ventral striatal activity with impulse control disorders in Parkinson's disease","volume":"25","author":"Rao","year":"2010","journal-title":"Mov. Disord."},{"issue":"Pt5","key":"10.1016\/j.parkreldis.2019.02.042_bib22","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/brain\/awp054","article-title":"Increased striatal dopamine release in parkinsonian patients with pathological gambling: a 11C raclopride PET study","volume":"132","author":"Steeves","year":"2009","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.parkreldis.2019.02.042_bib23","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.nbd.2012.06.021","article-title":"Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: a [11C] FLB-457 and PET study","volume":"48","author":"Ray","year":"2012","journal-title":"Neurobiol. Dis."},{"issue":"5","key":"10.1016\/j.parkreldis.2019.02.042_bib24","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/mds.23567","article-title":"Comparative neuropsychological profile of pathological gambling, hypersexuality, and compulsive eating in Parkinson's disease","volume":"26","author":"Vitale","year":"2011","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.parkreldis.2019.02.042_bib25","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/mds.25291","article-title":"Nirenberg Prospective cohort study of impulse control disorders in Parkinson's disease","volume":"28","author":"Bastiaens","year":"2013","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.parkreldis.2019.02.042_bib26","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.parkreldis.2011.01.009","article-title":"Dopamine agonist-triggered pathological behaviors: surveillance in the PD clinic reveals high frequencies","volume":"17","author":"Hassan","year":"2011","journal-title":"Park. Relat. Disord."},{"issue":"3","key":"10.1016\/j.parkreldis.2019.02.042_bib27","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1212\/WNL.0000000000005816","article-title":"Longitudinal analysis of impulse control disorders in Parkinson disease","volume":"91","author":"Corvol","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.parkreldis.2019.02.042_bib28","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/archneurol.2009.294","article-title":"Dopamine agonist withdrawal syndrome in Parkinson disease","volume":"67","author":"Rabinak","year":"2010","journal-title":"Arch. Neurol."},{"issue":"8","key":"10.1016\/j.parkreldis.2019.02.042_bib29","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/jnnp-2013-306787","article-title":"Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study","volume":"85","author":"Garcia-Ruiz","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"8","key":"10.1016\/j.parkreldis.2019.02.042_bib30","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/ene.13034","article-title":"EUROPAR and the IPMDS Non-Motor-PD-Study Group, A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists","volume":"23","author":"Rizos","year":"2016","journal-title":"Eur. J. Neurol."},{"issue":"14","key":"10.1016\/j.parkreldis.2019.02.042_bib31","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1002\/mds.25636","article-title":"Levodopa infusion improves impulsivity and dopamine dysregulation syndrome in Parkinson's disease","volume":"28","author":"Catal\u00e1n","year":"2013","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.parkreldis.2019.02.042_bib32","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/WNF.0000000000000091","article-title":"Infusion therapies and development of impulse control disorders in advanced Parkinson disease: clinical experience after 3 Years' follow-up","volume":"38","author":"Todorova","year":"2015","journal-title":"Clin. Neuropharmacol."},{"issue":"suppl 1","key":"10.1016\/j.parkreldis.2019.02.042_bib33","first-page":"S133","article-title":"Assessment of impulse control disorders in Parkinson's patients with infusion therapies: a single center experience","volume":"28","author":"Todorova","year":"2013","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.parkreldis.2019.02.042_bib34","first-page":"79","article-title":"Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and nonmotor symptoms and impact on patient's and caregiver's quality of life","volume":"16","author":"Fasano","year":"2012","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"5","key":"10.1016\/j.parkreldis.2019.02.042_bib35","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11910-016-0647-4","article-title":"Neuropsychiatric issues in Parkinson's disease","volume":"16","author":"Cooney","year":"2016","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"1","key":"10.1016\/j.parkreldis.2019.02.042_bib36","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s13311-013-0238-x","article-title":"Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease","volume":"11","author":"Connolly","year":"2014","journal-title":"Neurotherapeutics"},{"issue":"9","key":"10.1016\/j.parkreldis.2019.02.042_bib37","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1212\/WNL.0000000000000729","article-title":"Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study","volume":"83","author":"Papay","year":"2014","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.parkreldis.2019.02.042_bib38","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ana.22029","article-title":"Pathological gambling in Parkinson disease is reduced by amantadine","volume":"68","author":"Thomas","year":"2010","journal-title":"Ann. Neurol."},{"issue":"9","key":"10.1016\/j.parkreldis.2019.02.042_bib39","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1212\/WNL.0b013e3182840678","article-title":"Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers","volume":"80","author":"Okai","year":"2013","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.parkreldis.2019.02.042_bib40","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/jnnp.2006.102061","article-title":"Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease","volume":"78","author":"Smeding","year":"2007","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5854","key":"10.1016\/j.parkreldis.2019.02.042_bib41","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.1146157","article-title":"Hold your horses: impulsivity, deep brain stimulation, and medication in parkinsonism","volume":"318","author":"Frank","year":"2007","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.parkreldis.2019.02.042_bib42","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jocn.2012.07.020","article-title":"Impulse control and related behaviors after bilateral subthalamic stimulation in patients with Parkinson's disease","volume":"20","author":"Kim","year":"2013","journal-title":"J. Clin. Neurosci."},{"issue":"Pt 5","key":"10.1016\/j.parkreldis.2019.02.042_bib43","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/brain\/aws078","article-title":"Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours","volume":"135","author":"Lhomm\u00e9e","year":"2012","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.parkreldis.2019.02.042_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029768","article-title":"Effects of STN and GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome","volume":"7","author":"Moum","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.parkreldis.2019.02.042_bib45","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/jnnp-2013-307214","article-title":"Impulse control behaviours in patients with Parkinson's disease after subthalamic deep brain stimulation: de novo cases and 3-year follow-up","volume":"86","author":"Amami","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.parkreldis.2019.02.042_bib46","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1474-4422(18)30035-8","article-title":"EARLYSTIM study group, Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial","volume":"17","author":"Lhomm\u00e9e","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2019.02.042_bib47","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/mds.26223","article-title":"International validation of a behavioral scale in Parkinson's disease without dementia","volume":"30","author":"Rieu","year":"2015","journal-title":"Mov. Disord."},{"issue":"7","key":"10.1016\/j.parkreldis.2019.02.042_bib48","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1205158","article-title":"EARLYSTIM Study Group, Neurostimulation for Parkinson's disease with early motor complications","volume":"368","author":"Schuepbach","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.parkreldis.2019.02.042_bib49","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1136\/jnnp-2017-316373","article-title":"Subthalamic stimulation and neuropsychiatric symptoms in Parkinson's disease: results from a long-term follow-up cohort study","volume":"89","author":"Abbes","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"10","key":"10.1016\/j.parkreldis.2019.02.042_bib50","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.parkreldis.2010.08.015","article-title":"Validation of diagnostic criteria for apathy in Parkinson's disease","volume":"16","author":"Drijgers","year":"2010","journal-title":"Park. Relat. Disord."},{"issue":"2","key":"10.1016\/j.parkreldis.2019.02.042_bib51","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.eurpsy.2008.09.001","article-title":"Proposed diagnostic criteria for apathy in Alzheimer's disease and other neuropsychiatric disorders","volume":"24","author":"Robert","year":"2009","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.parkreldis.2019.02.042_bib52","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/gps.2508","article-title":"Diagnostic criteria for apathy in clinical practice","volume":"26","author":"Mulin","year":"2011","journal-title":"Int. J. Geriatr. Psychiatry"},{"issue":"2","key":"10.1016\/j.parkreldis.2019.02.042_bib53","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/ane.12282","article-title":"The associations between fatigue, apathy, and depression in Parkinson's disease","volume":"131","author":"Skorvanek","year":"2015","journal-title":"Acta Neurol. Scand."},{"issue":"6","key":"10.1016\/j.parkreldis.2019.02.042_bib54","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/mds.21316","article-title":"Characteristics of apathy in Parkinson's disease","volume":"22","author":"Dujardin","year":"2007","journal-title":"Mov. Disord."},{"issue":"13","key":"10.1016\/j.parkreldis.2019.02.042_bib55","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1002\/mds.22246","article-title":"Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia","volume":"23","author":"Pagonabarraga","year":"2008","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.parkreldis.2019.02.042_bib56","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1474-4422(15)00019-8","article-title":"Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment","volume":"14","author":"Pagonabarraga","year":"2015","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.parkreldis.2019.02.042_bib57","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/mds.26208","article-title":"Apathy in Parkinson's disease: a systematic review and meta-analysis","volume":"30","author":"den Brok","year":"2015","journal-title":"Mov. Disord."},{"issue":"7","key":"10.1016\/j.parkreldis.2019.02.042_bib58","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/mds.26170","article-title":"Parkinson's Progression Markers Initiative, Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease","volume":"30","author":"Weintraub","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2019.02.042_bib59","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.parkreldis.2017.08.008","article-title":"Apathy in drug-na\u00efve patients with Parkinson's disease","volume":"44","author":"Liu","year":"2017","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2019.02.042_bib60","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/mds.26058","article-title":"Apathy in untreated early-stage Parkinson disease: relationship with other non-motor symptoms","volume":"29","author":"Dujardin","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2019.02.042_bib61","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/mds.26077","article-title":"The onset of nonmotor symptoms in Parkinson's disease (The ONSET PD Study)","volume":"30","author":"Pont-Sunyer","year":"2014","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.parkreldis.2019.02.042_bib62","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1037\/a0019650","article-title":"The independent influence of apathy and depression on cognitive functioning in Parkinson's disease","volume":"24","author":"Butterfield","year":"2010","journal-title":"Neuropsychology"},{"issue":"16","key":"10.1016\/j.parkreldis.2019.02.042_bib63","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1002\/mds.22843","article-title":"Apathy may herald cognitive decline and dementia in Parkinson's disease","volume":"24","author":"Dujardin","year":"2009","journal-title":"Mov. Disord."},{"issue":"10","key":"10.1016\/j.parkreldis.2019.02.042_bib64","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s11910-017-0788-0","article-title":"Imaging the etiology of apathy, anxiety, and depression in Parkinson's disease: implication for treatment","volume":"17","author":"Thobois","year":"2017","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"Pt 9","key":"10.1016\/j.parkreldis.2019.02.042_bib65","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1093\/brain\/aww162","article-title":"The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson's disease","volume":"139","author":"Maillet","year":"2016","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.parkreldis.2019.02.042_bib66","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1155\/2013\/851890","article-title":"Apathy in Parkinson's disease: diagnosis, neuropsychological correlates, pathophysiology and treatment","volume":"27","author":"Santangelo","year":"2013","journal-title":"Behav. Neurol."},{"issue":"Pt 4","key":"10.1016\/j.parkreldis.2019.02.042_bib67","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/brain\/awq032","article-title":"Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation","volume":"133","author":"Thobois","year":"2010","journal-title":"Brain"},{"issue":"7","key":"10.1016\/j.parkreldis.2019.02.042_bib68","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/mds.21949","article-title":"Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom","volume":"23","author":"Czernecki","year":"2008","journal-title":"Mov. Disord."},{"issue":"Pt 5","key":"10.1016\/j.parkreldis.2019.02.042_bib69","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/brain\/awt067","article-title":"Parkinsonian apathy responds to dopaminergic stimulation of D2\/D3 receptors with piribedil","volume":"136","author":"Thobois","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2019.02.042_bib70","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1176\/jnp.4.2.134","article-title":"Reliability, validity, and clinical correlates of apathy in Parkinson's disease","volume":"4","author":"Starkstein","year":"1992","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"issue":"11","key":"10.1016\/j.parkreldis.2019.02.042_bib71","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/gps.1215","article-title":"A randomized, controlled, clinical trial of activity therapy for apathy in patients with dementia residing in long-term care","volume":"19","author":"Politis","year":"2004","journal-title":"Int. J. Geriatr. Psychiatry"},{"issue":"4","key":"10.1016\/j.parkreldis.2019.02.042_bib72","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/gps.1279","article-title":"The effects of psychosocial methods on depressed, aggressive and apathetic behaviors of people with dementia: a systematic review","volume":"20","author":"Verkaik","year":"2005","journal-title":"Int. J. Geriatr. Psychiatry"},{"issue":"7","key":"10.1016\/j.parkreldis.2019.02.042_bib73","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/JGP.0b013e31822be242","article-title":"Nonpharmacological management of apathy in dementia: a systematic review","volume":"20","author":"Brodaty","year":"2012","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.parkreldis.2019.02.042_bib74","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/jnnp-2013-306439","article-title":"Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial","volume":"85","author":"Devos","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.parkreldis.2019.02.042_bib75","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1176\/appi.neuropsych.11090210","article-title":"Are selective serotonin reuptake inhibitors associated with greater apathy in Parkinson's disease?","volume":"24","author":"Zahodne","year":"2012","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.parkreldis.2019.02.042_bib76","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1212\/WNL.0b013e3181ebdd79","article-title":"Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease","volume":"75","author":"Weintraub","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2019.02.042_bib77","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12883-016-0610-7","article-title":"Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease","volume":"16","author":"Hauser","year":"2016","journal-title":"BMC Neurol."},{"key":"10.1016\/j.parkreldis.2019.02.042_bib78","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.parkreldis.2013.02.018","article-title":"Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER","volume":"19","author":"Chaudhuri Ray","year":"2013","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2019.02.042_bib79","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.clinthera.2009.01.012","article-title":"The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies","volume":"31","author":"Leentjens","year":"2009","journal-title":"Clin. Ther."},{"key":"10.1016\/j.parkreldis.2019.02.042_bib80","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jns.2018.08.003","article-title":"Rotigotine transdermal patch for the treatment of neuropsychiatric symptoms in Parkinson's disease: a meta-analysis of randomized placebo-controlled trials","volume":"393","author":"Wang","year":"2018","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.parkreldis.2019.02.042_bib81","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1176\/jnp.14.4.461","article-title":"Methylphenidate treats apathy in Parkinson's disease","volume":"14","author":"Chatterjee","year":"2002","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"issue":"7","key":"10.1016\/j.parkreldis.2019.02.042_bib82","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1474-4422(12)70106-0","article-title":"Parkgait-II study group, Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial","volume":"11","author":"Moreau","year":"2012","journal-title":"Lancet Neurol."},{"issue":"8","key":"10.1016\/j.parkreldis.2019.02.042_bib83","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/mds.21382","article-title":"Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group","volume":"22","author":"Ravina","year":"2007","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.parkreldis.2019.02.042_bib84","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1136\/jnnp.2008.166959","article-title":"The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's disease","volume":"80","author":"Aarsland","year":"2009","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.parkreldis.2019.02.042_bib85","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/mds.26432","article-title":"Minor hallucinations occur in drug-naive Parkinson's disease patients, even from the premotor phase","volume":"31","author":"Pagonabarraga","year":"2016","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.parkreldis.2019.02.042_bib86","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/gps.389","article-title":"A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia","volume":"16","author":"Aarsland","year":"2001","journal-title":"Int. J. Geriatr. Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.parkreldis.2019.02.042_bib87","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jns.2009.08.014","article-title":"Epidemiology of psychosis in Parkinson's disease","volume":"289","author":"Fenelon","year":"2010","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.parkreldis.2019.02.042_bib88","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/mds.26121","article-title":"Behavioral effects of levodopa","volume":"30","author":"Beaulieu-Boire","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2019.02.042_bib89","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archneurol.2010.166","article-title":"A 12-year population-based study of psychosis in Parkinson disease","volume":"67","author":"Forsaa","year":"2010","journal-title":"Arch. Neurol."},{"issue":"6","key":"10.1016\/j.parkreldis.2019.02.042_bib90","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/mds.21956","article-title":"The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years","volume":"23","author":"Hely","year":"2008","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.parkreldis.2019.02.042_bib91","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/jnnp-2016-314832","article-title":"Risk factors for early psychosis in PD: insights from the Parkinson's Progression markers initiative","volume":"88","author":"Ffytche","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.parkreldis.2019.02.042_bib92","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.parkreldis.2012.03.004","article-title":"Attention and visual dysfunction in Parkinson's disease","volume":"18","author":"Botha","year":"2012","journal-title":"Park. Relat. Disord."},{"issue":"7","key":"10.1016\/j.parkreldis.2019.02.042_bib93","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/mds.25003","article-title":"Psychosis in Parkinson's disease without dementia: common and comorbid with other non-motor symptoms","volume":"27","author":"Lee","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2019.02.042_bib94","first-page":"3256542","article-title":"Management of psychosis in Parkinson's disease: emphasizing clinical subtypes and pathophysiological mechanisms of the condition","volume":"2017","author":"Taddei","year":"2017","journal-title":"Parkinsons Dis"},{"issue":"9","key":"10.1016\/j.parkreldis.2019.02.042_bib95","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.parkreldis.2014.06.018","article-title":"Arizona Parkinson's Disease Consortium, Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations","volume":"20","author":"Jacobson","year":"2014","journal-title":"Park. Relat. Disord."},{"issue":"11","key":"10.1016\/j.parkreldis.2019.02.042_bib96","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/ene.13390","article-title":"Ventral striatal dopaminergic defect is associated with hallucinations in Parkinson's disease","volume":"24","author":"Jaakkola","year":"2017","journal-title":"Eur. J. Neurol."},{"issue":"7","key":"10.1016\/j.parkreldis.2019.02.042_bib97","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.parkreldis.2015.04.005","article-title":"Structural and functional neuroimaging in patients with Parkinson's disease and visual hallucinations: a critical review","volume":"21","author":"Lenka","year":"2015","journal-title":"Park. Relat. Disord."},{"issue":"10","key":"10.1016\/j.parkreldis.2019.02.042_bib98","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/ene.13376","article-title":"The role of neurotransmitters in the development of Parkinson's disease-related psychosis","volume":"24","author":"Factor","year":"2017","journal-title":"Eur. J. Neurol."},{"issue":"11","key":"10.1016\/j.parkreldis.2019.02.042_bib99","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/mds.25157","article-title":"Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease","volume":"27","author":"Ravina","year":"2012","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.parkreldis.2019.02.042_bib100","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1001\/archneurol.2010.35","article-title":"Serotonin 2A receptors and visual hallucinations in Parkinson disease","volume":"67","author":"Ballanger","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.parkreldis.2019.02.042_bib101","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.pneurobio.2014.01.004","article-title":"Tricks of the mind: visual hallucinations as disorders of attention","volume":"116","author":"Shine","year":"2014","journal-title":"Prog. Neurobiol."},{"issue":"2","key":"10.1016\/j.parkreldis.2019.02.042_bib102","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrneurol.2016.200","article-title":"The psychosis spectrum in Parkinson disease","volume":"13","author":"Ffytche","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"Suppl 3","key":"10.1016\/j.parkreldis.2019.02.042_bib103","first-page":"S42","article-title":"The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease","volume":"26","author":"Seppi","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2019.02.042_bib104","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.parkreldis.2016.04.023","article-title":"Parkinson's disease, visual hallucinations and apomorphine: a review of the available evidence","volume":"27","author":"Borgemeester","year":"2016","journal-title":"Park. Relat. Disord."},{"issue":"1","key":"10.1016\/j.parkreldis.2019.02.042_bib105","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.parkreldis.2009.05.006","article-title":"Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations","volume":"16","author":"van Laar","year":"2010","journal-title":"Park. Relat. Disord."},{"issue":"4","key":"10.1016\/j.parkreldis.2019.02.042_bib106","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.26067","article-title":"EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease","volume":"30","author":"Martinez-Martin","year":"2015","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.parkreldis.2019.02.042_bib107","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00415-010-5793-z","article-title":"A 5- year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation","volume":"258","author":"Antonini","year":"2011","journal-title":"J. Neurol."},{"issue":"Suppl 1","key":"10.1016\/j.parkreldis.2019.02.042_bib108","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.parkreldis.2016.11.020","article-title":"The efficacy of apomorphine - a non-motor perspective","volume":"33","author":"Rosa-Grilo","year":"2016","journal-title":"Park. Relat. Disord."},{"issue":"7","key":"10.1016\/j.parkreldis.2019.02.042_bib109","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/mds.10450","article-title":"Coping strategies for visual hallucinations in Parkinson's disease","volume":"18","author":"Diederich","year":"2003","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.parkreldis.2019.02.042_bib110","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/wcs.94","article-title":"Visual hallucinations","volume":"1","author":"Collerton","year":"2010","journal-title":"Wiley Interdiscip Rev Cogn Sci."},{"issue":"1","key":"10.1016\/j.parkreldis.2019.02.042_bib111","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1468-1331.2012.03866.x","article-title":"Summary of the recommendations of the EFNS\/MDS-ES review on therapeutic management of Parkinson's disease","volume":"20","author":"Ferreira","year":"2013","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.parkreldis.2019.02.042_bib112","doi-asserted-by":"crossref","first-page":"j1951","DOI":"10.1136\/bmj.j1951","article-title":"Parkinson's disease: summary of updated NICE guidance","volume":"358","author":"Rogers","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.parkreldis.2019.02.042_bib113","doi-asserted-by":"crossref","first-page":"898.e1","DOI":"10.1016\/j.jamda.2015.06.021","article-title":"Impact of current antipsychotic medications on comparative mortality and adverse events in people with Parkinson disease psychosis","volume":"16","author":"Ballard C","year":"2015","journal-title":"J. Am. Med. Dir. Assoc."},{"issue":"5","key":"10.1016\/j.parkreldis.2019.02.042_bib114","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1001\/jamaneurol.2016.0031","article-title":"Association of antipsychotic use with mortality risk in patients with Parkinson disease","volume":"73","author":"Weintraub","year":"2016","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.parkreldis.2019.02.042_bib115","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/npp.2009.176","article-title":"A serotonin(2A) receptor inverse agonist, for the treatment of Parkinson's disease psychosis","volume":"35","author":"Meltzer","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"9916","key":"10.1016\/j.parkreldis.2019.02.042_bib116","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.parkreldis.2019.02.042_bib117","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2147\/NDT.S108948","article-title":"Update on the treatment of Parkinson's disease psychosis: role of pimavanserin","volume":"13","author":"Combs","year":"2017","journal-title":"Neuropsychiatric Dis. Treat."},{"issue":"5","key":"10.1016\/j.parkreldis.2019.02.042_bib118","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1755-5949.2010.00166.x","article-title":"Effects of cholinesterase inhibitors in Parkinson's disease dementia: a review of clinical data","volume":"17","author":"van Laar","year":"2011","journal-title":"CNS Neurosci. Ther."},{"issue":"2","key":"10.1016\/j.parkreldis.2019.02.042_bib119","doi-asserted-by":"crossref","first-page":"98","DOI":"10.14802\/jmd.15041","article-title":"Effect of rivastigmine on behavioral and psychiatric symptoms of Parkinson's disease dementia","volume":"8","author":"Oh","year":"2015","journal-title":"J Mov Disord"},{"issue":"7","key":"10.1016\/j.parkreldis.2019.02.042_bib120","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s40263-018-0540-6","article-title":"Assessment and management of neuropsychiatric symptoms in Parkinson's disease","volume":"32","author":"Mueller","year":"2018","journal-title":"CNS Drugs"},{"issue":"24","key":"10.1016\/j.parkreldis.2019.02.042_bib121","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa041470","article-title":"Rivastigmine for dementia associated with Parkinson's disease","volume":"351","author":"Emre","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.parkreldis.2019.02.042_bib122","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/mds.21077","article-title":"Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease","volume":"21","author":"Burn","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2019.02.042_bib123","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2018-318107","article-title":"Early use of donepezil against psychosis and cognitive decline in Parkinson's disease: a randomised controlled trial for 2 years","author":"Sawada","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"10","key":"10.1016\/j.parkreldis.2019.02.042_bib124","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S1474-4422(10)70194-0","article-title":"Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial","volume":"9","author":"Emre","year":"2010","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.parkreldis.2019.02.042_bib125","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S1474-4422(09)70146-2","article-title":"Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial","volume":"8","author":"Aarsland","year":"2009","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.parkreldis.2019.02.042_bib126","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1590\/0004-282X20150131","article-title":"Electroconvulsive therapy in Parkinson's disease","volume":"73","author":"Calder\u00f3n-Fajardo","year":"2015","journal-title":"Arq Neuropsiquiatr"},{"issue":"2","key":"10.1016\/j.parkreldis.2019.02.042_bib127","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/YCT.0b013e3181c18a3d","article-title":"Marked improvement of psychotic symptoms after electroconvulsive therapy in Parkinson disease","volume":"26","author":"Ueda","year":"2010","journal-title":"J. ECT"},{"issue":"7","key":"10.1016\/j.parkreldis.2019.02.042_bib128","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.pnpbp.2011.05.003","article-title":"Improvements in both psychosis and motor signs in Parkinson's disease, and changes in regional cerebral blood flow after electroconvulsive therapy","volume":"35","author":"Usui","year":"2011","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.parkreldis.2019.02.042_bib129","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.parkreldis.2016.04.009","article-title":"ICICLE-PD study group, Cognitive decline and quality of life in incident Parkinson's disease: the role of attention","volume":"27","author":"Lawson","year":"2016","journal-title":"Park. Relat. Disord."},{"issue":"11","key":"10.1016\/j.parkreldis.2019.02.042_bib130","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/mds.22158","article-title":"Striatal dopamine transporter imaging correlates with depressive symptoms and tower of London task performance in Parkinson's disease","volume":"23","author":"Rektorova","year":"2008","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.parkreldis.2019.02.042_bib131","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/mds.26956","article-title":"Striato-cortical connections in Parkinson's and Alzheimer's diseases: relation to cognition","volume":"32","author":"Anderkova","year":"2017","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.parkreldis.2019.02.042_bib132","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/mds.25857","article-title":"The neurobiological basis of cognitive impairment in Parkinson's disease","volume":"29","author":"Halliday","year":"2014","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.parkreldis.2019.02.042_bib133","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s00702-011-0674-x","article-title":"Mild cognitive impairment exists in Parkinson's disease","volume":"118","author":"Rektorova","year":"2011","journal-title":"J. Neural. Transm."},{"issue":"Suppl 1","key":"10.1016\/j.parkreldis.2019.02.042_bib134","doi-asserted-by":"crossref","first-page":"S159","DOI":"10.1016\/j.parkreldis.2015.09.053","article-title":"Parkinson's and Alzheimer's diseases: focus on mild cognitive impairment","volume":"22","author":"Korczyn","year":"2016","journal-title":"Park. Relat. Disord."},{"issue":"3","key":"10.1016\/j.parkreldis.2019.02.042_bib135","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/mds.24893","article-title":"Diagnostic criteria for mild cognitive impairment in Parkinson's disease: movement disorder society task force guidelines","volume":"27","author":"Litvan","year":"2012","journal-title":"Mov. Disord."},{"issue":"13","key":"10.1016\/j.parkreldis.2019.02.042_bib136","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1212\/01.wnl.0000338632.00552.cb","article-title":"Norwegian ParkWest Study Group, Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study","volume":"72","author":"Aarsland","year":"2009","journal-title":"Neurology"},{"issue":"Pt 11","key":"10.1016\/j.parkreldis.2019.02.042_bib137","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1093\/brain\/awp245","article-title":"The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort","volume":"132","author":"Williams-Gray","year":"2009","journal-title":"Brain"},{"issue":"10","key":"10.1016\/j.parkreldis.2019.02.042_bib138","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/gps.4261","article-title":"Mild cognitive impairment in Parkinson's disease and its progression onto dementia: a 16-year outcome evaluation of the Denbighshire cohort","volume":"30","author":"Hobson","year":"2015","journal-title":"Int. J. Geriatr. Psychiatry"},{"issue":"1","key":"10.1016\/j.parkreldis.2019.02.042_bib139","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085595","article-title":"Grey matter changes in cognitively impaired Parkinson's disease patients","volume":"9","author":"Rektorova","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.parkreldis.2019.02.042_bib140","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/mds.22381","article-title":"Amnestic mild cognitive impairment in Parkinson's disease: a brain perfusion SPECT study","volume":"24","author":"Nobili","year":"2009","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.parkreldis.2019.02.042_bib141","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00702-017-1703-1","article-title":"Arterial spin labelling detects posterior cortical hypoperfusion in non-demented patients with Parkinson's disease","volume":"124","author":"Syrimi","year":"2017","journal-title":"J. Neural. Transm."},{"issue":"1\u20134","key":"10.1016\/j.parkreldis.2019.02.042_bib142","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000334765","article-title":"Default mode network and extrastriate visual resting state network in patients with Parkinson's disease dementia","volume":"10","author":"Rektorova","year":"2012","journal-title":"Neurodegener. Dis."},{"issue":"Suppl 3","key":"10.1016\/j.parkreldis.2019.02.042_bib143","doi-asserted-by":"crossref","first-page":"S217","DOI":"10.3233\/JAD-132684","article-title":"Default mode network connectivity patterns associated with visual processing at different stages of Parkinson's disease","volume":"42","author":"Rektorova","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.parkreldis.2019.02.042_bib144","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.neuropsychologia.2017.09.034","article-title":"Neural evidence for defective top-down control of visual processing in Parkinson's and Alzheimer's disease","volume":"106","author":"Nemcova Elfmarkova","year":"2017","journal-title":"Neuropsychologia"},{"issue":"4","key":"10.1016\/j.parkreldis.2019.02.042_bib145","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.26968","article-title":"International Parkinson and Movement Disorder Society (IPMDS)-Neuroimaging Study Group, the role of high-field magnetic resonance imaging in parkinsonian disorders: pushing the boundaries forward","volume":"32","author":"Lehericy","year":"2017","journal-title":"Mov. Disord."},{"issue":"12","key":"10.1016\/j.parkreldis.2019.02.042_bib146","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/mds.21507","article-title":"Clinical diagnostic criteria for dementia associated with Parkinson's disease","volume":"22","author":"Emre","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2019.02.042_bib147","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.parkreldis.2016.05.018","article-title":"Speech prosody impairment predicts cognitive decline in Parkinson's disease","volume":"29","author":"Rektorova","year":"2016","journal-title":"Park. Relat. Disord."},{"issue":"4","key":"10.1016\/j.parkreldis.2019.02.042_bib148","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrneurol.2017.27","article-title":"Cognitive decline in Parkinson disease","volume":"13","author":"Aarsland","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"Pt 3","key":"10.1016\/j.parkreldis.2019.02.042_bib149","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/brain\/awm322","article-title":"EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up","volume":"131","author":"Bonanni","year":"2008","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.parkreldis.2019.02.042_bib150","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.parkreldis.2008.05.014","article-title":"Serum inflammatory biomarkers in Parkinson's disease","volume":"15","author":"Dufek","year":"2009","journal-title":"Park. Relat. Disord."},{"issue":"1","key":"10.1016\/j.parkreldis.2019.02.042_bib151","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2217\/BMM.14.105","article-title":"The utility of \u03b1-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature","volume":"10","author":"Simonsen","year":"2016","journal-title":"Biomark. Med."},{"key":"10.1016\/j.parkreldis.2019.02.042_bib152","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/bs.irn.2016.12.001","article-title":"Cerebrospinal fluid biomarkers of cognitive decline in Parkinson's disease","volume":"132","author":"Johar","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"issue":"10","key":"10.1016\/j.parkreldis.2019.02.042_bib153","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/mds.20527","article-title":"A systematic review of prevalence studies of dementia in Parkinson's disease","volume":"20","author":"Aarsland","year":"2005","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.parkreldis.2019.02.042_bib154","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/archneur.60.3.387","article-title":"Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study","volume":"60","author":"Aarsland","year":"2003","journal-title":"Arch. Neurol."},{"issue":"4","key":"10.1016\/j.parkreldis.2019.02.042_bib155","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00702-017-1821-9","article-title":"Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies","volume":"125","author":"Jellinger","year":"2018","journal-title":"J. Neural. Transm."},{"issue":"Pt 5","key":"10.1016\/j.parkreldis.2019.02.042_bib156","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1093\/brain\/awr031","article-title":"Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?","volume":"134","author":"Compta","year":"2011","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.parkreldis.2019.02.042_bib157","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.parkreldis.2008.02.007","article-title":"Vascular pathology in patients with idiopathic Parkinson's disease","volume":"15","author":"Rektor","year":"2009","journal-title":"Park. Relat. Disord."},{"issue":"4","key":"10.1016\/j.parkreldis.2019.02.042_bib158","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/ana.23659","article-title":"Neuropathologic substrates of Parkinson disease dementia","volume":"72","author":"Irwin","year":"2012","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.parkreldis.2019.02.042_bib159","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/gps.4507","article-title":"Anticholinergic effect on cognition (AEC) of drugs commonly used in older people","volume":"32","author":"Bishara","year":"2017","journal-title":"Int. J. Geriatr. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.parkreldis.2019.02.042_bib160","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1159\/000295665","article-title":"Effects of dopamine agonists on neuropsychiatric symptoms of Parkinson's disease","volume":"7","author":"Rektorov\u00e1","year":"2010","journal-title":"Neurodegener. Dis."},{"issue":"3","key":"10.1016\/j.parkreldis.2019.02.042_bib161","first-page":"CD006504","article-title":"Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease","author":"Rolinski","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.parkreldis.2019.02.042_bib162","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1136\/jnnp-2014-307659","article-title":"Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis","volume":"86","author":"Wang","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"10","key":"10.1016\/j.parkreldis.2019.02.042_bib163","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/mds.25098","article-title":"Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study","volume":"27","author":"Dubois","year":"2012","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.parkreldis.2019.02.042_bib164","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/mds.26617","article-title":"MODERATO Investigators, Rasagiline for mild cognitive impairment in Parkinson's disease: a placebo-controlled trial","volume":"31","author":"Weintraub","year":"2016","journal-title":"Mov. Disord."},{"issue":"7","key":"10.1016\/j.parkreldis.2019.02.042_bib165","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/mds.26236","article-title":"Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study","volume":"30","author":"Mamikonyan","year":"2015","journal-title":"Mov. Disord."},{"issue":"3\u20134","key":"10.1016\/j.parkreldis.2019.02.042_bib166","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000377676","article-title":"The effect of creatine and coenzyme q10 combination therapy on mild cognitive impairment in Parkinson's disease","volume":"73","author":"Li","year":"2015","journal-title":"Eur. Neurol."},{"issue":"6","key":"10.1016\/j.parkreldis.2019.02.042_bib167","article-title":"Cognitive and psychiatric effects of STN versus GPi deep brain stimulation in Parkinson's disease: a meta-analysis of randomized controlled trials","volume":"11","author":"Wang","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.parkreldis.2019.02.042_bib168","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1017\/S1092852917000062","article-title":"Neuropsychological performance changes following subthalamic versus pallidal deep brain stimulation in Parkinson's disease: a systematic review and metaanalysis","volume":"23","author":"Elgebaly","year":"2018","journal-title":"CNS Spectr."},{"issue":"11","key":"10.1016\/j.parkreldis.2019.02.042_bib169","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1586\/14737175.6.11.1695","article-title":"Criteria for deep-brain stimulation in Parkinson's disease: review and analysis","volume":"6","author":"Moro","year":"2006","journal-title":"Expert Rev. Neurother."},{"issue":"1","key":"10.1016\/j.parkreldis.2019.02.042_bib170","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mds.26890","article-title":"Current applications and limitations of surgical treatments for movement disorders","volume":"32","author":"Krack","year":"2017","journal-title":"Mov. Disord."},{"issue":"9","key":"10.1016\/j.parkreldis.2019.02.042_bib171","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.parkreldis.2015.06.012","article-title":"Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease - clinical practice recommendations","volume":"21","author":"Trenkwalder","year":"2015","journal-title":"Park. Relat. Disord."},{"issue":"10","key":"10.1016\/j.parkreldis.2019.02.042_bib172","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.parkreldis.2015.07.020","article-title":"National Steering Committees, Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: consensus from an international survey and discussion program","volume":"21","author":"Odin","year":"2015","journal-title":"Park. Relat. Disord."},{"issue":"8","key":"10.1016\/j.parkreldis.2019.02.042_bib173","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/mds.23663","article-title":"The role of the inferior frontal gyri in cognitive processing of patients with Parkinson's disease: a pilot rTMS study","volume":"26","author":"Srovnalova","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2019.02.042_bib174","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/bs.irn.2017.05.009","article-title":"Noninvasive brain stimulation and implications for nonmotor symptoms in Parkinson's disease","volume":"134","author":"Rektorov\u00e1","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"issue":"21","key":"10.1016\/j.parkreldis.2019.02.042_bib175","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1212\/WNL.0000000000002145","article-title":"Cognitive training in Parkinson disease: a systematic review and meta-analysis","volume":"85","author":"Leung","year":"2015","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.parkreldis.2019.02.042_bib176","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.brs.2015.07.043","article-title":"Double-blind randomized trial of tDCS versus sham in Parkinson patients with mild cognitive impairment receiving cognitive training","volume":"8","author":"Biundo","year":"2015","journal-title":"Brain Stimul"},{"issue":"7","key":"10.1016\/j.parkreldis.2019.02.042_bib177","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/arclin\/acx092","article-title":"Cognitive rehabilitation in Parkinson's disease: is it feasible?","volume":"32","author":"Biundo","year":"2017","journal-title":"Arch. Clin. Neuropsychol."},{"issue":"1","key":"10.1016\/j.parkreldis.2019.02.042_bib178","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/mds.26484","article-title":"The therapeutic potential of exercise to improve mood, cognition, and sleep in Parkinson's disease","volume":"31","author":"Reynolds","year":"2016","journal-title":"Mov. Disord."}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802019300872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802019300872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:16:31Z","timestamp":1761178591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802019300872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":178,"alternative-id":["S1353802019300872"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2019.02.042","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current treatment of behavioral and cognitive symptoms of Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2019.02.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}